ClinicalTrials.gg
RecruitingNCT05182697Updated May 16, 2025

SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

An interventional study of SCI-210 and Oral CBD oil in Autism Spectrum Disorder (ASD), sponsored by SciSparc. Recruiting at 1 site in Israel. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by SciSparc · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
5 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Autism Spectrum Disorder with a site in Israel — 5 open to participants now, 6 under way, none of them phase 3. Autism Spectrum Disorder · Israel.

Planned enrollment
8th of 19
60 · median 59
Started
2024
the only one that year
No phase
14 of 29
3 open now
Registered
18th of 29
by date

Among the 29 studies in Autism Spectrum Disorder with a site in Israel, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 14 with no phase, and was the 18th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

5 of the 29 studies in Autism Spectrum Disorder with a site in Israel are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 5 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Autism Spectrum Disorder with a site in Israel, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)

Read the detailed description

The innovative compound SCI-210 consists of CBD oil combined with CannAmide (PEA formulation) using the "entourage effect" to enhance efficacy of CBD. It is believed that PEA potentiates anandamide responses in non-vascular tissues. This effect is called "entourage effect". The "entourage effect" can be achieved by enhancing the action of endogenous anandamide through an increase in the affinity for receptors and/or a decrease in enzymatic degradation of anandamide (primarily by fatty acid amide hydrolase, FAAH). Thus, the combination of CBD oil with PEA is believed to be more effective than CBD oil alone, while AEs are not increased by the addition of the natural substance PEA.

SCI-210 has not been tested in clinical trials before, but anecdotal evidence of combined use of CBD and CannAmide in ASD patients has been accumulated in recent months. The evidence suggests the beneficial effects of the combination in alleviating ASD symptoms with no reported adverse events associated with the treatment.

03

Conditions studied

  • Autism Spectrum Disorder (ASD)
04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged between 5 and 18 years of age (inclusive)
  2. Diagnosis of ASD confirmed by the ADOS-2 and criteria
  3. Moderate or greater behavioral problems as measured by a rating of moderate or higher (≥4) on the Clinical Global Impression-Severity (CGI-S)
  4. Presence of a parent/legal guardian who is able to consent for their participation and completes assessments regarding the child's development and behavior throughout the study
  5. Patients eligible for cannabis treatment as regulated by the Israeli Ministry of Health, as out lined in the Medical Cannabis unit circular on Licenses for cannabis use, Procedure number 106, version 5 dated Jan 2021

Exclusion criteria

Exclusion Criteria:

  1. Children who are already receiving cannabis, antipsychotic drugs, or stimulants.
  2. Children with heart, liver, renal or hematological disorders.
  3. History of active seizure disorder or epilepsy; patients who are seizure free for more than 3 years can take part in the study
  4. Exposure to any agent in the 30 days prior to trial onset.
  5. A current psychiatric diagnosis of bipolar disorder, major depressive disorder (MDD), psychosis, schizophrenia, or post-traumatic stress disorder (PTSD)
  6. Subjects who have had changes in non-exclusionary psychotropic medications within 4 weeks of initiation of trial.
  7. Allergic to cannabinoids or PEA tablet components.
  8. History of substance abuse (including alcohol abuse or dependence) or laboratory evidence of drug abuse on the Visit 1 drug-screening panel.
  9. Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he or she were to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SCI-210

    Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily

    Drug: SCI-210

  • Active comparator
    CBD oil

    CBD- active CBD oil with twice daily and CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.

    Drug: Oral CBD oil

Interventions

  • DrugSCI-210

    Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily

  • CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)

    Evaluation of the safety of SCI-210 in the treatment of Autism Spectrum Disorders (ASD) throughout the 24 week treatment period. Adverse effects will be assessed using an adverse effects checklist (AEC) containing 19 items from the Liverpool Adverse Events Profile (LAEP) in addition to 15 items that have been used previously to assess side effects of CBD. These will be compared between the groups. Dropout rates from study will also be compared between these groups.

    Time frame: 24 weeks

  2. Evaluation of the efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)

    Evaluation of the efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD) throughout the 24 week treatment period. The primary outcome measures of the study will be the Clinical Global Impressions-Improvement (CGI-I) performed by a clinician. These will be completed at the beginning (Time 0), middle (4 weeks) and end (8 weeks) of each stage. Efficacy of treatment will be evaluated by comparing the change in CGI-I scores during the different periods of the study between the two treatment and control groups.

    Time frame: 24 weeks

  3. Evaluation of the efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)

    Evaluation of the efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD) throughout the 24 week treatment period. The primary outcome measures of the study will be the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire performed by a clinician. These will be completed at the beginning (Time 0), middle (4 weeks) and end (8 weeks) of each stage. Efficacy of treatment will be evaluated by comparing the change in ABC-C scores during the different periods of the study between the two treatment and control groups.

    Time frame: 24 weeks

Secondary outcomes

  1. Evaluate the safety of SCI-210 in children with ASD.

    Evaluate the safety of SCI-210 in children with ASD throughout the 24 week treatment periodAdverse effects will be assessed using an adverse effects checklist (AEC) containing 19 items from the Liverpool Adverse Events Profile (LAEP) in addition to 15 items that have been used previously to assess side effects of CBD. These will be compared between the groups. Dropout rates from study will also be compared between these groups.

    Time frame: 24 weeks

  2. Evaluate the tolerability of SCI-210 in children with ASD.

    Evaluate the tolerability of SCI-210 in children with ASD throughout the 24 week treatment period Adverse effects will be assessed using an adverse effects checklist (AEC) containing 19 items from the Liverpool Adverse Events Profile (LAEP) in addition to 15 items that have been used previously to assess side effects of CBD. These will be compared between the groups. Dropout rates from study will also be compared between these groups.

    Time frame: 24 weeks

  3. Assess the efficacy of SCI-210 in reducing disruptive behaviors among children with ASD

    Parents will fill out the following questionnaire at the beginning (Time 0) of the trial and at the end of the first (8 weeks) and second (20 weeks) stage: The Social Responsiveness Scale (SRS) will be used to estimate changes in the social abilities of the child. A total composite score between 60 and 65 is associated with mild to moderate deficits in social interaction. Scores between 66 and 75 are considered to display a moderate deficit in social interaction, and a score greater than 76 is considered severe and strongly associated with the clinical diagnosis of ASD

    Time frame: 20 weeks

  4. Assess the efficacy of SCI-210 in reducing sleep problems among children with ASD

    Parents will fill out the following questionnaire at the beginning (Time 0) of the trial and at the end of the first (8 weeks) and second (20 weeks) stage: The Children's Sleep Habit Questionnaire (CSHQ) will be used to estimate changes in the sleep quality of the child. A Total Sleep Disturbances score is calculated as the sum of all CSHQ scored questions, and can range from 33 to 99. A Total Sleep Disturbances score of over 41 indicates a pediatric sleep disorde.

    Time frame: 20 weeks

  5. Assess the efficacy of SCI-210 in reducing ASD symptoms among children with ASD.

    Children will participate in the following assessment at the beginning (Time 0) of the trial and at the end of the first (8 weeks) and second (20 weeks) stage: The Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2) will be used to estimate changes in core ASD symptoms. The comparison score ranges from 1-10, where 1 indicates minimal-to-no evidence of autism-related symptoms and 10 indicates a high level of impairment.

    Time frame: 20 weeks

  6. Assess the efficacy of SCI-210 in improving adaptive behaviors among children with ASD

    Parents will fill out the following questionnaire at the beginning (Time 0) of the trial and at the end of the first (8 weeks) and second (20 weeks) stage: The Adaptive Behavior Assessment System 3rd edition (ABAS-3) will be used to estimate changes in the adaptive behaviors of the child. The ratings given for each skill area are converted into a score from 1 to 19, with 1 being the lowest and 19 being the highest, and scores of 8 to 12 being in the Average range

    Time frame: 20 weeks

  7. Assess the efficacy of SCI-210 in improving language abilities among children with ASD

    Children will participate in the following assessment at the beginning (Time 0) of the trial and at the end of the first (8 weeks) and second (20 weeks) stage: The Preschool Language Scale will be used to estimate changes in language abilities. A standard score of 100 on this scale represents the performance of the typical student of a given age. Standard scores between 85 and 115 correspond to one standard deviation below and above the mean, respectively; scores within this range are considered to be within normal limits.

    Time frame: 20 weeks

  8. Assess the effects of SCI-210 on eye tracking measures when viewing social movies.

    Eye tracking assessment will be performedat the beginning (Time 0) of the trial and at the end of the first (8 weeks) and second (20 weeks) stage Eye tracking while watching movies will be performed to estimate changes in the way the children observe movies with social information (e.g., children playing). This will quantify changes in the social preferences of the child.

    Time frame: 20 weeks

07

Study locations

1 of 1 sites recruiting
  • Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, Israel
    Be'er-Sheva, 8457108, Israel
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for May 2026, 27 months after the start.

Of 827 interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Jan 10, 2022
StartActual
Feb 21, 2024
Primary completionEst.
May 2026
CompletionEst.
Jun 2026
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05182697
Lead sponsor
SciSparc
Collaborators
Negev Autism Center Soroka University Medical Center
Responsible party
Sponsor
First posted
Jan 10, 2022
Start date
Feb 21, 2024
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
May 16, 2025

Study contacts

Adi Zuloff-Shani, PhD
Contact
adi@scisparc.com
972-3-7175777
Gal Meiri, MD, MHA
principal investigator · Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, Israel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion